Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Gossamer Bio is a clinical stage biopharmaceutical company with a promising pipeline of products in the fields of immunology, inflammation, and oncology, specifically its lead product Seralutinib. Key opinion leaders (KOLs) have shown support for the drug in relevant geographies and for moderate-to-high-risk patients, with management stating that physicians have shown particular interest in the approximately 26.5-meter and 25-30 meter placebo-adjusted benefits in North America and Europe, respectively. This geographic and physician support, coupled with the potential to address unmet needs in difficult-to-treat populations, makes Gossamer Bio's stock outlook positive for the foreseeable future.

Bears say

Gossamer Bio is facing several challenges that could negatively impact the company's future success. While the PROSERA CT FRI data provide some support for seralutinib's potential, it is not enough to outweigh the miss on the primary endpoint and issues with the high placebo response. In addition, the company is facing regulatory and commercial challenges, with the need for additional capital and a potential narrow patient population target for seralutinib. On top of that, Gossamer Bio also faces competition from both generic players and other established pharmaceutical companies.

GOSS has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 6 analysts, GOSS has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.